What Are HEK293 Cells and Why Are They Used in Research?

HEK293 cells are a line of human cells originally derived from an embryonic kidney in 1973, transformed with fragments of adenovirus DNA so they would grow indefinitely in the lab. They have become one of the most widely used cell lines in biomedical research and biomanufacturing, prized for how easily they take up foreign DNA and how readily they can be coaxed into producing proteins, viral vectors, and other biological products. Their story, though, involves more than a simple origin and a list of uses: decades of cultivation have reshaped their genome in surprising ways, and the gap between their name and their actual biology is wider than most researchers casually acknowledge.

How HEK293 Cells Came to Exist

The “HEK” stands for human embryonic kidney, and the “293” refers to the experiment number in a series of transformation attempts. In 1973, a researcher at Leiden University in the Netherlands took kidney cells from a legally aborted human fetus of unknown parentage and exposed them to sheared fragments of adenovirus type 5 DNA.¹ The idea was straightforward: normal human cells stop dividing after a certain number of passages, but viral DNA can override that limit. The gamble paid off with experiment 293, which yielded a cell line that kept growing.

What actually integrated into the cellular genome was a stretch of DNA from the left-hand end of the adenovirus 5 genome. Early mapping studies showed that the viral sequence inserted into the host DNA ran from roughly the first few hundred base pairs up to somewhere between base pairs 4,123 and 5,372 on the viral map.² That stretch encodes genes known as E1A and E1B, which are the viral tools for hijacking a cell’s growth controls. The original characterization confirmed that the cells transcribed RNA from this integrated adenoviral segment, establishing the molecular basis for their immortalization.³ Those integrated viral genes are still there in every HEK293 descendant today, and they turn out to be directly useful for certain manufacturing applications, as we’ll see.

Why Researchers Reach for HEK293 Cells

Three practical qualities have made HEK293 the workhorse it is. First, these cells accept foreign DNA with remarkable efficiency. Transfection, the process of introducing new genetic material into a cell, routinely achieves success rates in the range of 40 to 60 percent with optimized protocols.⁴ That level of transfectability outperforms many other cell types; one comparison using chitosan-DNA nanoparticles found HEK293 cells took up DNA more readily than osteoblast-like cells or mesenchymal stem cells.⁵

Second, HEK293 cells grow fast. Third, they can be adapted to grow in suspension in serum-free media, which matters enormously for scaling up production. Growing cells in suspension means you can use large stirred-tank bioreactors rather than stacking trays of cells on surfaces, and dropping the serum removes a variable, inconsistent animal-derived ingredient from the process.⁶ That combination of easy transfection, rapid division, and industrial scalability is hard to find in a single cell line.

A Genome That Never Sits Still

Despite the tidy name, HEK293 cells no longer resemble normal kidney cells in any meaningful genomic sense. They carry a pseudotriploid karyotype, meaning they have roughly three copies of most chromosomes instead of the usual two. Their genome is riddled with large-scale deletions, duplications, and chromosomal rearrangements, and these keep accumulating over time.¹ The cells are also classified as female in origin, based on the presence of multiple X chromosomes and no Y chromosome, though “female” in the context of a heavily rearranged genome is a loose descriptor at best.⁷

What makes this more than an academic footnote is that the genome drifts differently depending on how the cells are handled. A comparison of HEK293 stocks from different labs and cell banks found that the mean chromosome number and the specific chromosomal abnormalities vary between supposedly identical lines.⁷ A separate genomic comparison of derivative lines confirmed that closely related sublines share similar copy number variation profiles, but the further a line has been cultivated and manipulated, the more its genome diverges from the original.⁸ This means “HEK293” in one lab may behave somewhat differently from “HEK293” in another, and researchers who treat all 293-derived lines as interchangeable are making an assumption the genomics does not fully support.

The Family Tree of Derivative Lines

Over the decades, scientists have engineered a whole family of HEK293 variants, each tailored for a specific purpose. The most widely known is HEK293T, which carries a temperature-sensitive version of the SV40 large T antigen. That antigen lets the cell amplify any DNA vector containing an SV40 origin of replication, dramatically boosting protein output during transient transfection experiments. The T antigen also binds and inhibits the tumor suppressor p53, which likely contributes to additional genomic instability in this subline.⁹ Genomic comparisons have confirmed that 293T is among the most genetically diverged progeny lines relative to the original HEK293.¹⁰

HEK293FT is a further-engineered variant designed for lentiviral vector production, frequently used in the production of vectors for CAR-T cell therapy. A recently developed suspension-adapted version of this line grew at greater than 93 percent viability and maintained stable cell density over 35 passages, yielding up to 5 × 10⁹ infectious viral units from a single one-liter batch.¹¹

Then there is HEK293S GnTI⁻, a variant missing a particular glycosylation enzyme. This line produces proteins with simplified, uniform sugar structures, which is a boon for structural biologists who need homogeneous protein samples for techniques like X-ray crystallography or cryo-electron microscopy.¹² Each of these sublines traces back to the same 1973 experiment, but decades of selective engineering have made them functionally distinct tools.

Manufacturing Viral Vectors for Gene Therapy

Probably the highest-profile application of HEK293 cells right now is producing adeno-associated virus (AAV) vectors for gene therapy. AAV is a small, non-pathogenic virus that researchers hollow out and fill with a therapeutic gene, then deliver to patients. Making AAV in large quantities is difficult, but HEK293 cells are well suited to the task because they already carry those integrated adenovirus E1 genes, which happen to be part of the “helper” machinery AAV needs to replicate.

The standard approach, called triple transfection, introduces three plasmids into HEK293 cells simultaneously: one carrying the therapeutic gene, one carrying the AAV structural genes, and one supplying additional adenoviral helper functions. Using suspension-adapted HEK293 cells grown in animal-component-free media, this method can yield more than 100,000 vector genome particles per cell, or above 10¹⁴ particles per liter of culture.¹³ Researchers have continued refining the helper gene requirements, recently showing that only three adenoviral genes (E2A, L4-22K, and VA RNA I) are needed for high-titer AAV production in HEK293 cells, challenging the long-standing assumption that an additional gene called E4orf6 was necessary.¹⁴

Work on the DNA vectors themselves has also pushed yields higher. Substituting conventional plasmids with backbone-minimized “nanoplasmid” constructs in suspension HEK293 platforms has achieved up to a tenfold increase in vector genome titer under matched conditions.¹⁵ These incremental improvements matter because gene therapy doses can require enormous quantities of virus, and manufacturing bottlenecks have been one of the biggest obstacles to getting approved gene therapies to patients.

Protein Production and the Glycosylation Question

Beyond viral vectors, HEK293 cells are used to produce recombinant proteins for both research and therapy. Being human cells, they fold and modify proteins in ways that closely resemble what happens naturally in human tissue. This is a real advantage when the goal is a therapeutic protein destined for injection into a patient, because the post-translational modifications, especially the sugar chains (glycans) attached to the protein surface, influence how the body recognizes, uses, and clears the drug.

The comparison to Chinese hamster ovary (CHO) cells, the dominant platform for biopharmaceutical manufacturing, is instructive. For a study comparing how 24 hard-to-produce human proteins fared in HEK293 versus CHO, about a third showed improved secretion when produced in HEK293 cells, with the most heavily glycosylated proteins benefiting the most.¹⁶ HEK293 cells also avoid a specific pitfall of CHO cells: they do not produce Neu5Gc, a non-human sugar that CHO-derived products sometimes carry. An analysis of erythropoietin (EPO) made in HEK293 cells found no Neu5Gc or alpha-Gal, both of which can provoke immune responses in patients, whereas CHO-derived EPO contained Neu5Gc in about 5 percent of its glycan structures.¹⁷

But HEK293 glycosylation has its own problems. Proteins produced in these cells tend to carry high levels of terminal N-acetylgalactosamine (GalNAc) and relatively low sialylation compared to proteins made in CHO cells or found naturally in human plasma.¹⁸ When a therapeutic protein lacks sialic acid caps on its glycans, the body recognizes and clears it faster via receptors in the liver, which shortens the drug’s effective life in the bloodstream.¹⁹ Glyco-engineering efforts are underway to fix this, modifying the HEK293 glycosylation machinery so the cells add proper sialic acid caps while still avoiding the non-human sugars that CHO cells introduce. Until those engineered lines are fully mature, the rapid-clearance issue is a genuine limitation for using standard HEK293 cells to make certain biotherapeutics.

Drug Screening and Ion Channel Research

A completely different reason HEK293 cells appear on lab benches has nothing to do with manufacturing anything. Pharmacologists use them as a blank canvas for studying individual receptor proteins. The basic technique involves inserting the gene for a single receptor, ion channel, or signaling protein into HEK293 cells, then using electrophysiology or biochemical assays to study how that protein responds to drugs, toxins, or other molecules.

HEK293 cells work well for this because they express relatively few endogenous receptors of the types pharmacologists typically study, which keeps the background noise low. Researchers have used them extensively to characterize ligand-gated ion channels like P2X receptors, where combining electrophysiology with targeted mutations has revealed how these channels activate and how drugs block or modulate them.²⁰ One study, for example, expressed P2X receptors in HEK293 cells to measure how toluene, a commonly abused solvent, affects their function.²¹

There is a caveat, though. HEK293 cells are not as electrically silent as once assumed. Patch-clamp recordings have revealed that these cells express endogenous voltage-gated sodium currents, with peak amplitudes ranging from under 100 picoamps to over 800 picoamps, and the majority of cells showing currents in the 100 to 400 picoamp range. The responsible channel turned out to be Nav1.7, a sodium channel isoform that is actually a major drug target for pain research.²² Anyone studying voltage-gated sodium channels in HEK293 cells needs to account for this endogenous current, or risk confusing it with the channel they actually introduced.

Structural Biology and Membrane Proteins

Membrane proteins, the molecules embedded in cell surfaces that serve as receptors, transporters, and signal relays, are notoriously difficult to produce for structural studies. They need a lipid environment to fold properly, and bacterial expression systems usually cannot provide that. HEK293 cells offer a near-native human lipid and folding environment, making them increasingly popular for producing the full-length human membrane proteins used in X-ray crystallography and cryo-EM.²³

The GnTI⁻ variant mentioned earlier is especially useful here. Because it produces proteins with homogeneous, simplified sugar structures, crystallographers do not have to contend with the heterogeneous glycan clouds that normally decorate protein surfaces and interfere with crystal formation. Detailed protocols now exist for producing milligram quantities of purified human membrane proteins from this cell line using baculovirus-mediated gene delivery, a hybrid approach that combines insect-virus efficiency with human-cell protein processing.¹²

Growing HEK293 Cells at Industrial Scale

For any of the manufacturing applications described above, scaling up from a flask on a lab bench to a bioreactor producing liters of product requires adapting HEK293 cells to suspension growth in chemically defined, serum-free media. This is not trivial. The adaptation process typically takes weeks and involves careful tuning of media components to maintain high viability while preventing the cells from clumping together.

Recent work has shown that balancing iron and calcium concentrations in the medium is particularly important: iron affects how well the cells take up DNA during transfection, while calcium influences whether cells aggregate into clumps that starve the interior cells of nutrients and oxygen.²⁴ One systematic adaptation study achieved the transition from adherent to serum-free suspension culture in about a month while keeping viability above 90 percent throughout.²⁵

The shift from serum-containing to chemically defined media also removes a regulatory headache. Serum is an animal product, and regulators require extensive testing to ensure it does not introduce contaminants like prions or adventitious viruses into a manufacturing process. Chemically defined media sidestep that concern entirely, which is one reason the move toward serum-free HEK293 suspension culture has accelerated as gene therapy products have moved into clinical trials and commercial manufacturing.

What HEK293 Cells Are Not

The name “human embryonic kidney” creates a persistent misconception: that these cells are kidney cells. After fifty years of cultivation and genomic upheaval, they bear little resemblance to any normal human tissue. Their gene expression profile has shifted dramatically from anything you would find in a kidney, and the integrated adenoviral genes have fundamentally altered their growth behavior. Several studies have noted that HEK293 cells express markers more consistent with neuronal precursor cells than with mature kidney epithelium, likely because the original kidney tissue contained a mixed population and the transformation preferentially selected for a particular cell type. The endogenous expression of Nav1.7 sodium channels fits this picture.

They are also not embryonic stem cells. The “embryonic” in the name refers to the developmental stage of the fetus from which the original kidney cells were taken, not to a stem-cell-like state. HEK293 cells cannot differentiate into other tissue types the way embryonic stem cells can. They are a transformed, immortalized line with a specific and limited repertoire of behaviors, shaped by half a century of laboratory selection pressure.

Nor are they a single uniform entity. As genomic studies have documented, the HEK293 you order from one cell bank may differ meaningfully from the HEK293 in the freezer down the hall. Sublines show different chromosome numbers, different patterns of gene deletion and duplication, and different gene expression profiles depending on their passage history and the conditions under which they have been maintained.¹⁰ For most routine applications this variation is tolerable, but for tightly controlled manufacturing of clinical-grade products, it means that characterizing and banking a specific working cell stock is essential. The genome does not wait around for you to finish your experiments.